1 Additional Information and Where to Find It Communications related to each of Fortitude and HeartSciences, their respective businesses and the Proposed Transaction may be deemed solicitation material in respect of the Proposed Transaction. In connection with the Proposed Transaction, HeartSciences filed a preliminary proxy statement on Schedule 14A with the U.S. Securities and Exchange Commission (the “ SEC ”) on July 27, 2026 and may file additional relevant materials with the SEC. Followi…

Entry into a Material Definitive Agreement On August 12, 2026, HeartSciences Inc. (the “ Company ” or “ HeartSciences ”) sold and issued to Fortitude Mining Holdings, Inc., a Delaware corporation (“ Fortitude ”), an aggregate of 411,522 shares (the “ Shares ”) of HeartSciences common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price of $2.43 per Share (the “ Purchase Price ”) in a private placement (the “ PIPE Investment ”). The Purchase Price represented the 30 tr…

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 4, 2026, HeartSciences Inc. (the “Company” or “HeartSciences”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the Nasdaq Listing Rule 5550(b)(1) (“Rule 5550(b)(1)”), which requires companies listed on the Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockhol…

of this Current Report, including Exhibit 99.1 attached hereto, related to each of Fortitude and HeartSciences, their respective businesses and the Proposed Transaction may be deemed solicitation material in respect of the Proposed Transaction. In connection with the Proposed Transaction, HeartSciences has filed and may file additional relevant materials with the U.S. Securities and Exchange Commission (“SEC”), including a preliminary proxy statement on Schedule 14A. Following the filing of a…

Entry into a Material Definitive Agreement. On July 27, 2026, HeartSciences Inc., a Texas corporation (“ HeartSciences ”), entered into Amendment No. 1 to the Agreement and Plan of Merger (the “ Amendment ”) with Fortitude Mining Holdings, Inc., a Delaware corporation (“ Seller ”), Fortitude Mining HoldCo, LLC, a Delaware limited liability company and a direct wholly-owned subsidiary of Seller (“ Fortitude ”), and Cordis Acquisition, LLC, a Delaware limited liability company and a direct, who…

The filing describes amendments to the Employment Agreement for Danielle Watson, CFO of HeartSciences, in connection with a merger transaction.

Unregistered Sales of Equity Securities The disclosure required by this Item is included in

The filing describes an amendment to the Employment Agreement and a grant of restricted shares as part of a merger agreement, not a management change.

Unregistered Sales of Equity Securities The disclosure required by this Item is included in

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information regarding the Waiver set forth under

The shares of Parent Class A Common Stock and Parent Class V Common Stock issuable pursuant to the Merger Agreement are expected to be issued in transactions exempt from registration pursuant to Section 4(a)(2) under the Securities Act of 1933, as amended (the “ Securities Act ”). 5

The excerpt does not provide specific details about a departure, election, or appointment.

Entry into a Material Definitive Agreement Merger Agreement On June 23, 2026, HeartSciences Inc., a Texas corporation (“ HeartSciences ” or “ Parent ”), Fortitude Mining Holdings, Inc., a Delaware corporation (“ Seller ”), Fortitude Mining HoldCo, LLC, a Delaware limited liability company and a direct wholly-owned subsidiary of Seller (“ Fortitude ”), and Cordis Acquisition, LLC, a Delaware limited liability company and a direct, wholly-owned subsidiary of Parent (“ Merger Sub ”), entered int…

Chief Operating Officer, Corporate Secretary, Director — Mark Hilz: Mr. Hilz passed away following a period of illness.

of this Current Report and Exhibit 99.1 to this Current Report shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

The Company issued the Note to Streeterville in reliance on the exemption from registration provided for under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and Rule 506 promulgated thereunder. The Company relied on this exemption from registration for private placements based in part on the representations made by Streeterville, including representations with respect to its status as an accredited investor, as such term is defined in Rule 501(a) of the Sec…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information contained in

Entry into a Material Definitive Agreement. Note Purchase Agreement and Promissory Note On January 13, 2026, HeartSciences Inc. (the “Company” entered into a Note Purchase Agreement (the “Note Purchase Agreement”) with Streeterville Capital, LLC, an institutional investor (“Streeterville”), pursuant to which Streeterville purchased from the Company an unsecured promissory note in the amount of $3,605,000 (the “Note”), which included an original issue discount of $600,000 (the “OID”) and reimb…

Entry into a Material Definitive Agreement. On December 15, 2025, the Board of Directors of HeartSciences Inc. (the “Company”) approved a form of Indemnification Agreement (the “Indemnification Agreement”) to be entered into with each of its directors and executive officers (each, an “Indemnitee”). The Indemnification Agreement provides generally that the Company will indemnify each Indemnitee and advance expenses to each Indemnitee to the fullest extent permitted under Texas law and the Cert…

of this Current Report and Exhibit 99.1 to this Current Report shall not be deemed to be “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filings made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

The filing describes amendments to the equity incentive plan and grants of RSUs and share awards, which are routine administrative actions.

Unregistered Sales of Equity Securities The disclosure required by this Item is included in

Entry into a Material Definitive Agreement. As previously reported, HeartSciences Inc. (the “Company”) entered into a Loan and Security Agreement on April 24, 2020 (the “Original Loan Agreement”), as amended by Amendment No. 1 to the Loan and Security Agreement, dated September 30, 2021 (the “No. 1 Amendment”), Amendment No. 2 to the Loan and Security Agreement, dated November 3, 2021 (the “No. 2 Amendment”), Amendment No. 3 to the Loan and Security Agreement, dated May 24, 2022 (the “No. 3 A…

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. To the extent required by

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On September 16, 2025, HeartSciences Inc. (the “Company”) received formal notice from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with Nasdaq’s Minimum Stockholders’ Equity Requirement (as defined below) and the matter is now closed. As previously disclosed in the Company’s Current Report on F…